Trung Huynh
Stock Analyst at UBS
(4.23)
# 377
Out of 4,843 analysts
44
Total ratings
54.84%
Success rate
16.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Buy | $38 → $33 | $5.68 | +480.99% | 2 | May 13, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $19.84 | +91.53% | 2 | May 9, 2025 | |
| INSM Insmed | Maintains: Buy | $110 → $109 | $69.21 | +57.49% | 5 | May 9, 2025 | |
| AMGN Amgen | Maintains: Neutral | $319 → $315 | $283.54 | +11.10% | 4 | May 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $722.57 | +45.31% | 8 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $768 → $633 | $605.39 | +4.56% | 2 | Apr 30, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $23.45 | +6.61% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $47.85 | +12.85% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.91 | +266.49% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $2.63 | +394.30% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $153.58 | +13.95% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $76.40 | +64.92% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $185.62 | -8.42% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.37 | - | 1 | Mar 23, 2021 |
Jasper Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $5.68
Upside: +480.99%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $19.84
Upside: +91.53%
Insmed
May 9, 2025
Maintains: Buy
Price Target: $110 → $109
Current: $69.21
Upside: +57.49%
Amgen
May 2, 2025
Maintains: Neutral
Price Target: $319 → $315
Current: $283.54
Upside: +11.10%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $722.57
Upside: +45.31%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $768 → $633
Current: $605.39
Upside: +4.56%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $23.45
Upside: +6.61%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $47.85
Upside: +12.85%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.91
Upside: +266.49%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $2.63
Upside: +394.30%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $153.58
Upside: +13.95%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $76.40
Upside: +64.92%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $185.62
Upside: -8.42%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.37
Upside: -